310 likes | 503 Views
Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference 2008 Dr. John Climax Executive Chairman. Forward Looking Statements.
E N D
Merrill LynchGlobal Pharmaceutical, Biotechnology and Medical Device Conference 2008 Dr. John Climax Executive Chairman
Forward Looking Statements Certain statements contained herein including, without limitation, statements containing the words “believes,” “anticipates,” “intends,” “expects” and words of similar import, constitute forward-looking statements concerning the Company's operations, performance, financial condition and prospects. Because such statements involve known and unknown risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
The Journey So Far 1990 • Revenues $0.5 million • Staff 5 2006 • Revenues $456 million • EPS $1.33 • Staff 4,300 2007 Guidance • Revenues $615 - $625m • EPS $1. 82 - $1.85 • Staff 5,500 2008 Guidance • Revenues $750 - $770m • EPS $2.27 - $2.36 • Staff 6,250
Global Full Service Clinical Development EU 41% Revenue by Region ROW 6% US 53%
Global sites Conducting Clinical Trials in over 100 countries from 67 Locations in 37 countries 5600 Employees67 Locations37 Countries
Strong Market Environment with... • Fundamental R&D Spending Growth Trend 6%- 8% p.a. • Phase II / III pipelines strengthening • Increased Outsourcing • Being accelerated by activity & funding in Biotech / Speciality • Globalisation of clinical research • Cost containment pressures • Evidence that projects, where CROs are engaged, complete faster than “internal only” studies* • Growth c.15% p.a. since 2001* • Increasing Regulation • More patients/ more studies • Post marketing surveillance *Source: Tufts Centre for Study of Drug Development
…US Biotech Funding Environment continuing to grow Biotech fund raising ($billions) $Billion Source: Burrill and Company
…significant growth in the number of companies with active clinical projects,…. Number of companies running clinical projects Source: Informa Health
…which is enriching pipelines. 2002 – 2006 46% Growth Phase I – II Source: IMS R&D Focus, Dec 2006 and previous year SMRs
… and significant growth in the number of active INDs,… 49% Increase since 2000 Number of Active INDs Source: FDA
Strong Gross Business wins has led to… ICON Gross Business Wins - Last 9 Quarters ($ millions)
.. excellent Net New Business wins and very strong book to bill ratios… Net Business Wins Book to Bill Ratio
From this backlog, coverage of next 4 quarters revenues is robust…….. % coverage of next 4 quarters forecast revenues Value of backlog forecast to be earned in next 4 quarters
…..and the customer base continues to diversify. Client Concentration 2005, 2006, YTD 2007
YTD ‘07 Revenue Breakdown Estimate 2007 Revenue $620m* Revenue by Customer Segment Revenue by Therapeutic Area *Mid Point of Calendar year Guidance issued October 2007
Revenue Growth v Peers: Net Revenue CAGR between 2000 and 2006 *Source SEC Filings
Core Strategy is Organic Growth, with acquisitions adding new services or scale. • Capitalise on market fundamentals to drive organic growth in all business units. • Expand geographic footprint to exploit globalisation. • Pursue acquisitions to enhance depth and scale of current operations and to add additional complementary services e.g. • Phase I • Bioanalytical / Biomarkers • Therapeutic specialists • Safety / Phase IV • Patient Recruitment • Staffing • Cross-sell services to grow sales and margin
Recent Financial Performance ($ millions, except EPS; includes stock option expense)
Net Revenue CAGR in excess of 30% over 6 Years $760(E)** CAGR 31.6% FY2008(E) (E) *Mid Point of Calendar year Guidance issued October 2007 **Mid Point of Calendar year Guidance issued December, 2007
Earnings Per Share Growth $2.32(E)** CAGR 25.9% (E) FY2008(E) *Mid Point of Guidance issued October 2007 **Mid Point of Guidance issued December 2007
Quarterly Operating margins have beenimproving and …. Turnaround in Lab * Includes an estimated SFAS 123 non cash stock compensation charge for the 2005 figures
….further margin improvement should arisethrough 2008 • Further volume growth in Lab • Significantly improved performance from Phase I and Consultancy businesses • Bringing Japan from investment phase to profitability • Expanding margins in Phase II – IV through leverage
Investment Case Summary • Top Global Clinical CRO - #4 • Outstanding record of growth • Strong market fundamentals • Excellent strategic position • Strong balance sheet • Margin expansion opportunity